PURITY SPECIFICATIONS, STORAGE, AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT CONTRACT. JULY 9, 2022 - JULY 8, 2027

点击翻译按钮获取中文摘要

The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA) supports research and development of new medications for the treatment of drug addiction. The objective of this contract is to provide NIDA and other NIH Institutes (NINDS and NIMH) with a centralized confidential repository of compounds for evaluation as potential treatment agents, standards and screening agents. “This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”